Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Amarantus Bioscience Holdings (AMBS) Message Board

I think he answers your questions here. Basically

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 30070
Posted On: 01/28/2015 6:02:24 PM
Posted By: Ea$y Money
Re: MoneyTree #16097
I think he answers your questions here. Basically he's saying that we're to young and small for the market to have faith in both a therapeutics and DX division at this time, thus we're valued at .07-.08 because of the risk reward ratio. By selling off part of the DX it will generate income for both AMBS and shareholders thus bolstering our SP and showing the market we're still mainly focused on Manf, and Phenoguard going forward.

"As described in some detail in previous communications, we are committed to providing a return of capital to our shareholders via a potential spin-out of our Amarantus Diagnostics division. We believe it is important to separate our groundbreaking therapeutics, regenerative medicine and discovery platforms from the diagnostics business, in large part, because the metrics to evaluate these different businesses will create difficulties in the marketplace to unlock the value from each division:

Revenue-focused investors who specialize in diagnostics will view the expenses associated with our therapeutics division as a major distraction and drain on valuable resources;

Science and clinical development focused investors will view the revenue created by our diagnostic assets in the short term as insufficient to support a clinical development company and will question the costs associated to acquire such revenue; and

The management talents required to make each business succeed are quite different
."

- See more at: http://www.thechairmansblog.com/amarantus-bio...Qf1Nz.dpuf


(0)
(0)




Amarantus Bioscience Holdings (AMBS) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us